ClinicalTrials.gg
RecruitingNCT07423975ARTS-SAFEUpdated Oct 16, 2026

Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke

A Phase 2 interventional study of High-dose Anakinra and Low-dose Anakinra in Stroke Acute and Endovascular Treatment, sponsored by Beijing Tiantan Hospital. Recruiting at 6 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's title name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Tiantan Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital — 46 open to participants now, 47 under way, 15 of them phase 3. Ischemic Stroke · Beijing Tiantan Hospital.

Planned enrollment
64th of 77
159 · median 564
Started
2026
with 18 others
Phase 2
15 of 86
8 open now
Primary completion
2026-10
later than 16 of 46 live
Registered
76th of 86
by date

Among the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, this one is the 64th largest by planned enrollment of the 77 interventional ones that give a count, is one of 19 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 16 of the 46 other live ones, and was the 76th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

46 of the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

40 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.

Read the detailed description

Adult acute ischemic stroke patients who have achieved successful recanalization (defined as expanded thrombolysis in cerebral infarction [eTICI] 2b50-3) after endovascular thrombectomy within 24 hours of symptom onset will be enrolled in this trial. The enrolled patients have stroke due to Internal carotid artery (ICA), middle cerebral artery (MCA) M1 or M2 occlusions confirmed by CTA/MRA and with baseline National Institutes of Health Stroke Scale (NIHSS) score of 6-25. The eligible patients will be randomly assigned to receive high-dose Anakinra, low-dose Anakinra or standard medical treatment. The primary outcome is Infarct core growth reduction via MRI at 5-7 days.

03

Conditions studied

  • Stroke Acute
  • Endovascular Treatment

Browse trials for

Keywords

  • acute ischemic stroke
  • endovascular treatment
  • successful recanalization
  • Anakinra
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 159 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18-80 years old (both inclusive);
  • Acute ischemic stroke symptom onset within 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  • Pre-stroke modified Rankin scale (mRS) score ≤1;
  • Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (both inclusive);
  • Internal carotid artery (ICA) or middle cerebral artery (MCA) M1/M2 occlusions confirmed by CTA/MRA and responsible for the signs and symptoms of acute ischemic stroke;
  • Successful recanalization (eTICI 2b50-3) after endovascular treatment;
  • Written from patients or their legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  • Allergy to Anakinra;
  • NIHSS consciousness score 1a >2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or other neurological/mental illness such that the patient is not able to cooperate or unwilling to cooperate;
  • Unable to perform CTP or PWI;
  • Acute or past intracerebral hemorrhage (ICH) (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma) confirmed by CT or MRI;
  • Multiple arterial occlusion (e.g., bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  • (GFR) \<30 mL/min or serum creatinine level >2.5 mg/dL;
  • Suspected septic embolism or infective endocarditis;
  • Neutropenia (ANC \<1.5 × 109/L);
  • Known active or recurrent liver disease (including cirrhosis, and C; positive or indeterminate laboratory results), or (ALT)/aspartate aminotransferase (AST) levels >3 times the (ULN) or total >2 times ULN;
  • History of other than basal cell carcinoma of the skin;
  • History or evidence of active or latent tuberculosis infection, or presence of tuberculosis risk factors including but not limited to: close contact with active tuberculosis patients within the past 12 months;
  • Any terminal illness such that the patient would not be expected to survive more than 1 year;
  • Pregnant women, nursing mothers, or reluctance to use effective measures during the period of trial;
  • Unlikely to adhere to the trial protocol or follow-up;
  • Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  • Participation in other interventional clinical trials within the previous 3 months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    High-dose Anakinra+standard medical treatment

    100 mg loading dose Anakinra over 60 seconds within 0.5 hours after randomization, followed by consecutive 2mg/kg/h infusions over 24 hours. Standard treatment strategy will be in the discretion of site investigators according to guidelines.

    Drug: High-dose Anakinra

  • Experimental
    Low-dose Anakinra+standard medical treatment

    100 mg subcutaneous Anakinra over 60 seconds within 0.5 hours after randomization, followed by 100 mg administered twice daily for 3 days. Standard treatment strategy will be in the discretion of site investigators according to guidelines.

    Drug: Low-dose Anakinra

  • Other
    Standard medical treatment

    All enrolled patients receive standard early management and secondary prevention treatment according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.

    Other: Standard medical treatment

Interventions

07

What researchers measure

Primary outcomes

  1. Change in ischaemic lesion volume from baseline to 7±2 days or discharge from the hospital

    Time frame: 7±2 days or discharge from the hospital

Secondary outcomes

  1. Ordinal distribution of modified Rankin Scale (mRS) at 90 days

    Ordinal distribution of mRS at 90 days (shift analysis). The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  2. The proportion of patients who have a score of 0 or 1 on the modified Rankin Scale (mRS) at 90 days

    The proportion of patients with an mRS score ≤ 1 at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  3. The proportion of patients with an modified Rankin Scale (mRS) score of 0-2 at 90 days

    The proportion of patients with an mRS score of 0-2 at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  4. The proportion of patients with an modified Rankin Scale (mRS) score of 5-6 at 90 days

    The proportion of patients with an mRS score of 5-6 at 90 days. The mRS score is a seven-point ordered categorical scale from 0 to 6 for functional neurological outcome, with 0 indicating no neurological symptoms and 6 indicating death.

    Time frame: 90 days

  5. The rate of early neurological improvement at 72 hours

    The rate of early neurological improvement at 72 hours after randomization (defined as a National Institute of Health Stroke Scale \[NIHSS\] score ≤1 or ≥8 points improvement compared with the baseline). NIHSS is scores range from 0 to 42, with higher scores indicating more severe neurologic deficits.

    Time frame: 72 hours

  6. The median value of change in the National Institute of Health Stroke Scale (NIHSS) score at 7 days

    The median value of change in the National Institute of Health Stroke Scale (NIHSS) score at 7 days. NIHSS is scores range from 0 to 42, with higher scores indicating more severe neurologic deficits.

    Time frame: 7 days

  7. The proportion of complete recanalization at 24 hours after randomization

    Complete recanalization is defined as an Arterial Occlusion Lesion scale \[AOL\] score of 3 (scale range, 0 \[no recanalization\] to 3 \[complete recanalization\]).

    Time frame: 24 hours

  8. The proportion of improvement on reperfusion at 24 hours after randomization

    Improvement on reperfusion is defined as \>90% reduction in Tmax \> 6s lesion volume

    Time frame: 24 hours

  9. The proportion of symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage within 36 hours (as defined by Safe Implementation of Thrombolysis in Stroke Monitoring Study \[SITS-MOST\] criteria)

    Time frame: 36 hours

  10. The rate of malignant stroke resulting in herniation or craniectomy within 7 days

    Malignant stroke resulting in herniation or craniectomy within 7 days

    Time frame: 7 days

  11. The proportion of all-cause mortality

    All-cause mortality at 90 days

    Time frame: 90 days

  12. The proportion of serious adverse events (SAEs)

    Serious adverse events within 90 days

    Time frame: 90 days

08

Study locations

6 of 6 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 6 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Mar 2026 → Apr 2026, primary completion Sep 2026 → Oct 2026 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2026
First posted
Feb 20, 2026
StartActual
Apr 8, 2026was Mar 2026
Primary completionEst.
Oct 30, 2026was Sep 2026
CompletionEst.
Jan 30, 2027was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
5 sites added. Beijing tiantan hospital is now Recruiting
Show 5 added (5 China)
  • Luoyang Yiluo Hospital · Luoyang, China
  • People's Hospital of Queshan · Panlong, China
  • Puyang Oilfield General Hospital · Puyang, China
  • Linyi People's Hospital · Linyi, China
  • Weifang People's Hospital · Weifang, China
Oct 16, 2026
Start date
Mar 1, 2026→Apr 8, 2026 (actual)
Oct 16, 2026
Primary completion
Sep 30, 2026→Oct 30, 2026
Oct 16, 2026
Study completion
Dec 31, 2026→Jan 30, 2027
Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Infarct core growth reduction via magnetic resonance imaging (MRI) at 5-7 daysNow Change in ischaemic lesion volume from baseline to 7±2 days or discharge from the hospitalTime frame: 5-7 days → 7±2 days or discharge from the hospital
Oct 16, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedMalignantThe rate of malignant stroke resulting in herniation andor craniectomy within 7 daysTime frame: 7 days
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    5 sites added. Beijing tiantan hospital is now Recruiting
    Show 5 added (5 China)
    • Luoyang Yiluo Hospital · Luoyang, China
    • People's Hospital of Queshan · Panlong, China
    • Puyang Oilfield General Hospital · Puyang, China
    • Linyi People's Hospital · Linyi, China
    • Weifang People's Hospital · Weifang, China
    Start date Mar 1, 2026→Apr 8, 2026 (now actual)
    Primary completion Sep 30, 2026→Oct 30, 2026
    Study completion Dec 31, 2026→Jan 30, 2027
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Infarct core growth reduction via magnetic resonance imaging (MRI) at 5-7 daysNow Change in ischaemic lesion volume from baseline to 7±2 days or discharge from the hospitalTime frame: 5-7 days → 7±2 days or discharge from the hospital
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedMalignantThe rate of malignant stroke resulting in herniation andor craniectomy within 7 daysTime frame: 7 days
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07423975
Responsible party
Yunyun Xiong (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Feb 20, 2026
Start date
Apr 8, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Yunyun Xiong, professor
Contact
xiongyunyun@bjtth.org
86-10-59978350
Yunyun Xiong
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein

Start the discussion